|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.408 EUR | +0.87% |
|
+3.29% | -11.30% |
| May. 07 | GenSight Biologics S.A. announced that it expects to receive ?1.546199 million in funding | CI |
| Apr. 05 | GenSight: financial visibility assured until the end of April | CF |
April 26 (Reuters) - Gensight Biologics SA:
* EMA SAYS APPLICATION FOR MARKETING AUTHORISATION FOR THE ADVANCED THERAPY MEDICINAL PRODUCT LUMEVOQ WAS WITHDRAWN
* EMA: CHMP RECOMMENDED GRANTING EXTENSION OF INDICATION FOR SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 TO INCLUDE USE AS BOOSTER IN CHILDREN AGED 6-11
* EMA - CHMP RECOMMENDED OPFOLDA FOR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE II IN COMBINATION WITH CIPAGLUCOSIDASE ALFA
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 128.2 USD | -0.07% | +4.96% | 49.18B | ||
| 9.575 USD | +2.63% | -5.18% | 2.76B | ||
| 0.408 EUR | +0.87% | +3.29% | 34.14M | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -11.30% | 34.14M | |
| +7.72% | 111B | |
| +11.09% | 106B | |
| -12.26% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.79% | 16.81B | |
| +38.93% | 12.54B | |
| -24.51% | 8.09B |
GENSIGHT BIOLOGICS S.A. 
